摘要
目的观察T2DM患者艾塞那肽治疗前后血清成纤维细胞生长因子-21(FGF-21)水平的变化。方法本研究是一项在多中心临床试验受试者中进行的探索性研究,入选二甲双胍、胰岛素促泌剂单药或联合治疗血糖控制不佳的T2DM患者,予艾塞那肽治疗16周。分别于治疗前后测定血清FGF-21水平及相关代谢指标。结果共入组受试者240例,其中,203例完成干预和随访,平均年龄(49.5±9.9)岁,糖尿病病程4.75(2.33,8.25)年。治疗前平均HbA_1c和体重分别为(8.21±0.90)%和(79.93±15.00)kg,治疗后分别为(7.02±1.05)%和(77.94±14.76)kg(P<0.001)。治疗前后血清FGF-21水平分别为143.97(99.90,213.90)和151.27(108.06,224.14)pg/ml(P<0.05)。结论在二甲双胍、胰岛素促泌剂单药或联合治疗血糖控制不佳的T2DM患者中,添加艾塞那肽治疗16周不仅能有降糖和减重效应,还可升高血清FGF-21。
Objective Fibroblast growth factor-21 （FGF-21） plays an important role in regulating the metabolism of glucose and lipid. This study aims to investigate the effect of Exenatide on serum FGF- 21 level in patients with type 2 diabetes （T2DM）. Methods 240 T2DM patients inadequately controlled by monotherapy or combination therapy with Metformin and insulin secretagogues were recruited in this exploratory multicenter clinical trial. All the patients received an add-on therapy with Exenatide by subcutaneous injection for 16 weeks. Serum FGF-21 level and other metabolic parameters were measured before and after Exenatide treatment. Results Finally,203 subjects completed the treatment and follow- up, with mean age （49.5±.9） years and median diabetes duration 4.75 （2.33,8.25） years. The levels of HbA1 c and body weight significantly decreased after treatment [ （8.21± 0.90）%vs （7.02± 1.05）% and （79.93±15.00） vs （77.94 ± 14. 76） kg, respectively, P〈0. 0011. Serum FGF-21 level increased after treatment [151.27 （108.06,224.14） vs 143.97 （99.90,213.90） pg/ml, P〈0.05]. Conclusion In poorly controlled T2DM patients with Metformin and insulin secretagogues monotherapy or combination therapy, the addition of Exenatide treatement can not only effectively lower blood glucose and body weight, but also increase serum FGF-21 level.
作者
杨琨
王海宁
洪天配
魏蕊
杨进
YANG Kun WANG Hai-ning HONG Tian-pei et al(Department of Endocrinology, Peking University Third Hospital, Beijing 100191 , China)
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2017年第4期330-333,共4页
Chinese Journal of Diabetes
基金
国家自然科学基金(81400798
81400767
81570692
81670701)
北京市自然科学基金(7163233)
